GlassScriptPhysician profile
Carole Scharf
NPI 1053307884
$2,031.38
in general payments reported to CMS, 2019-2025
30 companies · $473 in 2025
The $473 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.08 · 2021: $13.58 · 2022: $125 · 2023: $673 · 2024: $689 · 2025: $473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,835.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,834.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $267.41 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Gt Medical Technologies, INC | $215.67 | 2025 | Gammatile |
| Astrazeneca Pharmaceuticals LP | $178.61 | 2022-2025 | Tagrisso |
| Regeneron Healthcare Solutions, INC. | $139.93 | 2019-2025 | Libtayo |
| Abbvie INC. | $136.28 | 2023-2024 | Venclexta |
| Novocure INC. | $131.71 | 2024 | Optune |
| Janssen Biotech, INC. | $130.65 | 2023-2025 | Erleada, Rybrevant, Tecvayli |
| Daiichi Sankyo INC. | $102.53 | 2023-2025 | Enhertu, Datroway |
| Progenics Pharmaceuticals, INC. | $100.57 | 2023 | Pylarify |
| Incyte Corporation | $99.08 | 2023-2025 | Monjuvi, Jakafi, Pemazyre |
| Takeda Pharmaceuticals U.S.A., INC. | $68.16 | 2023-2024 | Fruzaqla, Ninlaro |
| Gilead Sciences, INC. | $46.66 | 2023 | |
| Jazz Pharmaceuticals INC. | $40.27 | 2023-2024 | |
| Celgene Corporation | $38.96 | 2024 | Reblozyl |
| Blue Earth Diagnostics | $36.25 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $32.97 | 2023 | Imbruvica |
| Astellas Pharma US INC | $22.98 | 2024 | Padcev |
| Adaptive Biotechnologies Corporation | $22.34 | 2023 | Clonoseq |
| Taiho Oncology, INC. | $21.57 | 2023 | |
| Sumitomo Pharma America, INC. | $21.29 | 2024 | Orgovyx |
| Sobi, INC | $20.77 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.40 | 2025 | |
| Adc Therapeutics America, INC. | $19.78 | 2023 | |
| Pfizer INC. | $19.39 | 2024 | |
| Cumberland Pharmaceuticals, INC. | $17.56 | 2024 | Sancuso |
| Emd Serono, INC. | $17.41 | 2023 | Bavencio |
| Coherus Oncology, INC. | $16.84 | 2024 | |
| Lilly USA, LLC | $16.27 | 2024 | Verzenio, Jaypirca, Retevmo |
| Karyopharm Therapeutics INC. | $15.49 | 2023 | Xpovio |
| Boston Scientific Corporation | $13.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carole Scharf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.